SGMT Sagimet Biosciences Quick Ratio

Sagimet Biosciences (SGMT) is developing targeted liver therapies, leveraging the success of denifanstat before reaching a stable cash flow. The use of AI in molecule discovery and synthesis automation is accelerating processes, although human trials remain the responsibility of physicians. The strategy is based on securing a major partner for sales. The price trend on GURU.Markets, where the indicator stands at 43.26, confirms these data.

The ratio is calculated as the sum of cash and accounts receivable, excluding illiquid inventory. This metric determines the business's ability to instantaneously settle short-term obligations without selling off inventory. For Sagimet Biosciences (SGMT), such solvency is critical when financing late-stage development of liver disease drugs. By analyzing the quick ratio trend, an investor can assess the company's resilience to cash flow gaps.